Compare MIND & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | NTRB |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 71.7M |
| IPO Year | 1994 | N/A |
| Metric | MIND | NTRB |
|---|---|---|
| Price | $8.51 | $4.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 288.6K | 23.4K |
| Earning Date | 12-09-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $46,195,000.00 | $2,278,321.00 |
| Revenue This Year | $2.33 | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $22.14 | ★ N/A |
| Revenue Growth | 2.21 | ★ 12.69 |
| 52 Week Low | $4.45 | $3.72 |
| 52 Week High | $14.50 | $11.78 |
| Indicator | MIND | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 45.12 |
| Support Level | $7.47 | $4.60 |
| Resistance Level | $9.35 | $5.45 |
| Average True Range (ATR) | 0.65 | 0.37 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 34.01 | 64.79 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.